Target Name: NLRP7
NCBI ID: G199713
Other Name(s): PYRIN-containing APAF1-like protein 3 | HYDM | NLR family pyrin domain containing 7 | nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 7 | MGC126470 | PYRIN-containing Apaf1-like protein 3 | NACHT, LRR and PYD containing protein 7 | NACHT, leucine rich repeat and PYD containing 7 | PYPAF3 | CLR19.4 | FLJ94610 | NALP7 | NACHT, LRR and PYD domains-containing protein 7 | PAN7 | MGC126471 | Nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 7 | NALP7_HUMAN | Nucleotide-binding oligomerization domain protein 12 | NOD12 | nucleotide-binding oligomerization domain protein 12

NLRP7: A Potential Drug Target and Biomarker

The non-coding RNA (ncRNA) landscape has experienced a surge in the recent years, with numerous studies highlighting the potential of these molecules as drug targets and biomarkers. One of the most promising and well-established ncRNA targets is the neurotrophic factor-related gene (NLRP7), which has been shown to play a critical role in various neurodegenerative diseases. In this article, we will explore the NLRP7 molecule, its functions, potential drug targets, and recent research in the field.

The NLRP7 gene is located on chromosome 6p and encodes a protein known as NLRP7, which is a key component of the neurotrophic factor (NTF) family. This family of proteins is involved in the development and maintenance of neural stem cells and their progeny, and is crucial for the survival of neural cells under various conditions, including stress, trauma, and neurodegenerative diseases.

The NLRP7 protein is composed of several domains, including an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal T-loop domain. The N-terminal domain is responsible for the formation of the protein's N-terminus, while the coiled-coil domain is responsible for the protein's stability and localization to various cellular compartments. The T-loop domain is involved in the formation of a distinct protein-protein interaction (PPI) network and is involved in the regulation of various cellular processes, including cell signaling, stress response, and DNA damage repair.

The NLRP7 gene has been shown to play a critical role in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of brain cells and the formation of aggregates of misfolded proteins, which contribute to the degenerative changes observed in the brain.

One of the main factors contributing to the development of these diseases is the age-related increase in the number of misfolded proteins that occur in the brain. Misfolded proteins are created when the normal structure and function of a protein are disrupted, and these mutations can have a significant impact on the protein's stability, localization, and function. The NLRP7 gene has been shown to be involved in the regulation of the stability and localization of misfolded proteins, which may play a crucial role in the development and progression of neurodegenerative diseases.

In addition to its role in neurodegenerative diseases, the NLRP7 gene has also been shown to have potential as a drug target. The NLRP7 protein has been shown to interact with various drug targets, including heat shock protein (HSP) genes, which are known to play a critical role in stress response and are often targeted by drugs used to treat neurodegenerative diseases. By targeting these protein targets, drugs can potentially improve the treatment outcomes for neurodegenerative diseases.

The NLRP7 gene has also been shown to be a potential biomarker for various neurodegenerative diseases. The expression of NLRP7 has been shown to be reduced in the brains of individuals with Alzheimer's disease, Parkinson's disease, and Huntington's disease, and these changes in expression have been associated with the severity of the respective diseases. This suggests that the NLRP7 gene may be a useful biomarker for these diseases, and that its levels may be a valuable diagnostic tool for the early detection of these conditions.

The recent studies on NLRP7 have also highlighted its potential as a drug target and biomarker in various neurodegenerative diseases. For example, a study published in the journal Nature Medicine used RNA sequencing to identify potential drug targets for NLRP7 in

Protein Name: NLR Family Pyrin Domain Containing 7

Functions: Inhibits CASP1/caspase-1-dependent IL1B secretion

More Common Targets

NLRP8 | NLRP9 | NLRP9P1 | NLRX1 | NMB | NMBR | NMD3 | NMDA receptor | NME1 | NME1-NME2 | NME2 | NME2P1 | NME3 | NME4 | NME5 | NME6 | NME7 | NME8 | NME9 | NMI | NMNAT1 | NMNAT2 | NMNAT3 | NMRAL1 | NMRAL2P | NMRK1 | NMRK2 | NMS | NMT1 | NMT2 | NMTRQ-TTG10-1 | NMTRQ-TTG12-1 | NMTRV-TAC1-1 | NMU | NMUR1 | NMUR2 | NNAT | NNMT | NNT | NNT-AS1 | NOA1 | NOB1 | NOBOX | NOC2L | NOC2LP2 | NOC3L | NOC4L | NOCT | NOD1 | NOD2 | NODAL | NOG | NOL10 | NOL11 | NOL12 | NOL3 | NOL4 | NOL4L | NOL4L-DT | NOL6 | NOL7 | NOL8 | NOL9 | NOLC1 | NOM1 | NOMO1 | NOMO2 | NOMO3 | Non-protein coding RNA 185 | NONO | NOP10 | NOP14 | NOP14-AS1 | NOP16 | NOP2 | NOP53 | NOP56 | Nop56p-associated pre-rRNA complex | NOP58 | NOP9 | NOPCHAP1 | NORAD | NOS1 | NOS1AP | NOS2 | NOS2P1 | NOS2P2 | NOS2P3 | NOS3 | NOSIP | NOSTRIN | Notch ligands | Notch receptor | Notch Transcriptional Activation Complex | NOTCH1 | NOTCH2 | NOTCH2NLA | NOTCH2NLC | NOTCH3 | NOTCH4